Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9436IDB
  • |
  • Pages: 118
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.

Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anemia in Chronic Kidney Disease (Renal Anemia)-Overview

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anemia in Chronic Kidney Disease (Renal Anemia)-Companies Involved in Therapeutics Development

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

CCM Duopharma Biotech Bhd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Myungmoon pharmaceutical Co Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Xenetic Biosciences Inc

Zydus Cadila Healthcare Ltd

Anemia in Chronic Kidney Disease (Renal Anemia)-Drug Profiles

BPI-5014B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daprodustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPO-018B-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin zeta biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ErepoXen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erythropoietin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-2216-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-EPO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTZ-951-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDGN-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMP-0101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molidustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-EPO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peg-EPO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-EPO-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegylated erythropoietin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHEP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Renal Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roxadustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-17-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadadustat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products

Anemia in Chronic Kidney Disease (Renal Anemia)-Product Development Milestones

Featured News & Press Releases

May 25, 2017: FDA Advisory Committee Recommends Approval Of Pfizer Proposed Biosimilar To Epogen/Procrit Across All Indications

May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents

Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease

Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease

Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anemia

Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia

Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease

Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients

Aug 09, 2016: Kissei and JCR to Initiate a Phase III Clinical Trial of a Long-Acting Erythropoiesis-Stimulating Agent (Development Code: JR-131)

Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease

Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan

Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment

May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction

May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by 3SBio Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Aevi Genomic Medicine Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Akebia Therapeutics Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Amgen Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Bayer AG, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Biocad, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CCM Duopharma Biotech Bhd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CJ HealthCare Corp, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by FibroGen Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by GlaxoSmithKline Plc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Japan Tobacco Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Novartis AG, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Panacea Biotec Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pfizer Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PharmaEssentia Corp, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PhytoHealth Corp, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pieris Pharmaceuticals Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Xenetic Biosciences Inc, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects, H1 2017

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

CCM Duopharma Biotech Bhd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Myungmoon pharmaceutical Co Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

Xenetic Biosciences Inc

Zydus Cadila Healthcare Ltd

Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutic Products under Development, Key Players in Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutics, Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline Overview, Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline, Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline Assessment

select a license
Single User License
USD 2000 INR 138000
Site License
USD 4000 INR 276000
Corporate User License
USD 6000 INR 414000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com